J. C. Penney and 4 Popular Stocks With New Analyst Ratings and Price Targets
Gilead Sciences Inc. (NASDAQ:GILD): Current price $40.56
After the company reported that their Sofosbuvir drug, a Hepatitis C treatment, met its endpoints in Phase III trials, Stifel Nicolaus increased their price target on Gilead Sciences Inc. The firm expects additional data on the drug to move the stock higher next month, and they maintain a Buy rating on the stock.
CIGNA Corporation (NYSE:CI): Current price $60.17
After the company announced a deal with Berkshire Hathaway to exit their Variable Annuity Death Benefits and Guaranteed Minimum Income Benefit reinsurance runoff businesses, J.PMorgan expects shares of Cigna Corporation to be up 5% or more. The firm finds the deal terms favorable for Cigna, and said that the announcement removes an overhang on the stock’s valuation. J.PMorgan keeps an Overweight rating on Cigna shares.
Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.
General Growth Properties Inc. (NYSE:GGP): Current price $20.45
Stifel Nicolaus believes that General Growth Properties Inc.’s mall portfolio fundamentals are accelerating, and they believe that the Real Estate Investment Trust, is well-positioned to generate above average internal growth over the next few years. The firm maintains a $22.50 price target and Buy rating on the stock.
J. C. Penney Company, Inc. (NYSE:JCP): Current price $19.87
Morgan Stanley said that J.C. Penney Company, Inc.’s January store checks were “discouraging” and indicate heavy clearance levels and a greater than expected comp deterioration. The firm lowered their fourth quarter earnings per share estimate from (3c) to (30c) and sees downside risk to the Street’s 2013 estimates. Shares are Underweight rated with a $15 price target.
Carbonite Inc. (NASDAQ:CARB): Current price $10.14
After Carbonite Inc.reported stronger than expected fourth quarter results, Oppenheimer expects the company’s sales for small and medium businesses to accelerate, generating positive cash flow and share gains. The firm reiterates an Outperform rating on the stock.
Don’t Miss: Is Hologic a Worthwhile Investment?